Axon Enterprise, Inc. (NASDAQ:AXON) Shares Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 21.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,978 shares of the biotechnology company’s stock after purchasing an additional 1,255 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Axon Enterprise were worth $1,803,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. HB Wealth Management LLC lifted its stake in Axon Enterprise by 3.9% in the fourth quarter. HB Wealth Management LLC now owns 1,139 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 43 shares during the last quarter. UMB Bank n.a. lifted its stake in Axon Enterprise by 11.0% in the fourth quarter. UMB Bank n.a. now owns 444 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 44 shares during the last quarter. CWM LLC lifted its stake in Axon Enterprise by 1.8% in the third quarter. CWM LLC now owns 2,669 shares of the biotechnology company’s stock valued at $531,000 after buying an additional 46 shares during the last quarter. Lindbrook Capital LLC lifted its stake in Axon Enterprise by 43.3% in the fourth quarter. Lindbrook Capital LLC now owns 172 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 52 shares during the last quarter. Finally, Greenleaf Trust lifted its stake in Axon Enterprise by 3.6% in the third quarter. Greenleaf Trust now owns 1,540 shares of the biotechnology company’s stock valued at $306,000 after buying an additional 54 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

AXON has been the topic of a number of recent analyst reports. StockNews.com cut shares of Axon Enterprise from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. Needham & Company LLC restated a “buy” rating and set a $400.00 price objective on shares of Axon Enterprise in a research note on Wednesday. William Blair restated an “outperform” rating on shares of Axon Enterprise in a research note on Wednesday. JMP Securities lifted their price objective on shares of Axon Enterprise from $250.00 to $285.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 6th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “overweight” rating in a research note on Thursday, April 11th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Axon Enterprise currently has an average rating of “Moderate Buy” and an average target price of $312.64.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $302.41 on Thursday. The business’s 50-day moving average price is $302.15 and its 200 day moving average price is $260.29. The firm has a market cap of $22.82 billion, a P/E ratio of 131.48 and a beta of 0.93. Axon Enterprise, Inc. has a 52-week low of $175.37 and a 52-week high of $329.87. The company has a quick ratio of 2.66, a current ratio of 3.00 and a debt-to-equity ratio of 0.42.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.29. The firm had revenue of $432.14 million for the quarter, compared to analysts’ expectations of $418.97 million. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. As a group, sell-side analysts predict that Axon Enterprise, Inc. will post 2.44 earnings per share for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.